ArticleFrontiers in nutrition2026
Effectiveness of the low FODMAP diet in patients with irritable bowel syndrome and small intestine bacterial overgrowth syndrome.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- IBS and SIBO: Gut Microbiota, Pathophysiology, and Non-Pharmacological Interventions.Antibiotics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The low FODMAP diet (fermentable oligosaccharides, disaccharides, monosaccharides and polyols, LFD) t is used in patients diagnosed with Irritable Bowel Syndrome (IBS) as part of non-pharmacological treatment. This approach is also used in patients with Small Intestine Bacterial Overgrowth (SIBO) or Intestinal Methanogen Overgrowth (IMO), but research in this area is insufficient. To fill this gap, we decided to investigate the effect of a low FODMAP diet on various parameters in patients with IBS or SIBO or IMO. The primary end point of the study was to assess the effect of a low FODMAP diet on the severity of gastrointestinal symptoms in patients diagnosed with IBS or SIBO or IMO. Secondary end points included evaluation of patients' tolerability of the low FODMAP diet; assessment of potential difficulties in completing a low FODMAP diet and evaluation of the role of the dietitian in the implementation of a complete low FODMAP diet. Methods: The study was conducted using an original unvalidated questionnaire completed online by adult patients diagnosed with IBS according to Rome IV Criteria and/or SIBO/IMO patients diagnosed with hydrogen-methane breath test, treated with a low FODMAP diet. Results: A total of 98 out of 118 patients who were invited to participate took part in an online survey. The participants had previously followed a low FODMAP diet. 90.7% of IBS patients reported reduction of symptoms after LFD. The greatest reduction in symptom severity before and after the LFD was found for bloating (MD -5.03, Conclusion: Low FODMAP diet was well tolerated and reduced reported gastrointestinal symptoms, with the greatest effect on reducing bloating. The reduction in symptoms occurred independently of the initial diagnosis. Patients who completed both phases of the diet were taking antibiotics before the diet more likely to respond well to the low FODMAP diet. The diet proved difficult to follow, and more than half of the patients sought the support of a dietitian, which confirms the importance of such support.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.